The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Parkinson's Disease (PD) Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
The global Parkinson's Disease (PD) Drugs market size is expected to reach US$ 7419.9 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Parkinson's Disease (PD) Drugs in various end use industries. The expanding demands from the Hospital and Family, are propelling Parkinson's Disease (PD) Drugs market. Dopamine Agonist, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Monoamine Oxidase Inhibitors segment is estimated at % CAGR for the next seven-year period.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Parkinson's Disease (PD) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Parkinson's Disease (PD) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Parkinson's Disease (PD) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Parkinson's Disease (PD) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Parkinson's Disease (PD) Drugs covered in this report include Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen and Eisai, etc.
The global Parkinson's Disease (PD) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
Global Parkinson's Disease (PD) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Parkinson's Disease (PD) Drugs market, Segment by Type:
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Global Parkinson's Disease (PD) Drugs market, by Application
Hospital
Family
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Parkinson's Disease (PD) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Parkinson's Disease (PD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
The global Parkinson's Disease (PD) Drugs market size is expected to reach US$ 7419.9 million by 2029, growing at a CAGR of 4.3% from 2023 to 2029. The market is mainly driven by the significant applications of Parkinson's Disease (PD) Drugs in various end use industries. The expanding demands from the Hospital and Family, are propelling Parkinson's Disease (PD) Drugs market. Dopamine Agonist, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Monoamine Oxidase Inhibitors segment is estimated at % CAGR for the next seven-year period.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Parkinson's Disease (PD) Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Parkinson's Disease (PD) Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Parkinson's Disease (PD) Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Parkinson's Disease (PD) Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Parkinson's Disease (PD) Drugs covered in this report include Boehringer Ingelheim, GlaxoSmithKline, Novartis, Teva Pharmaceutical Industries, AbbVie, Abital Pharma, Addex Therapeutics, Biogen and Eisai, etc.
The global Parkinson's Disease (PD) Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Boehringer Ingelheim
GlaxoSmithKline
Novartis
Teva Pharmaceutical Industries
AbbVie
Abital Pharma
Addex Therapeutics
Biogen
Eisai
Eli Lilly
F. Hoffmann-La Roche
H. Lundbeck
Impax Laboratories
Kyowa Hakko Kirin
Otsuka Pharmaceutical
Pfizer
Global Parkinson's Disease (PD) Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Parkinson's Disease (PD) Drugs market, Segment by Type:
Dopamine Agonist
Monoamine Oxidase Inhibitors
Acetylcholinesterase Inhibitors
Glutamate Inhibitors
Global Parkinson's Disease (PD) Drugs market, by Application
Hospital
Family
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Parkinson's Disease (PD) Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Parkinson's Disease (PD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Parkinson's Disease (PD) Drugs Market Overview
1.1 Parkinson's Disease (PD) Drugs Product Overview
1.2 Parkinson's Disease (PD) Drugs Market Segment by Type
1.2.1 Dopamine Agonist
1.2.2 Monoamine Oxidase Inhibitors
1.2.3 Acetylcholinesterase Inhibitors
1.2.4 Glutamate Inhibitors
1.3 Global Parkinson's Disease (PD) Drugs Market Size by Type
1.3.1 Global Parkinson's Disease (PD) Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Parkinson's Disease (PD) Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Parkinson's Disease (PD) Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Parkinson's Disease (PD) Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Parkinson's Disease (PD) Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Parkinson's Disease (PD) Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Parkinson's Disease (PD) Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Parkinson's Disease (PD) Drugs Sales Breakdown by Type (2018-2023)
2 Global Parkinson's Disease (PD) Drugs Market Competition by Company
2.1 Global Top Players by Parkinson's Disease (PD) Drugs Sales (2018-2023)
2.2 Global Top Players by Parkinson's Disease (PD) Drugs Revenue (2018-2023)
2.3 Global Top Players by Parkinson's Disease (PD) Drugs Price (2018-2023)
2.4 Global Top Manufacturers Parkinson's Disease (PD) Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Parkinson's Disease (PD) Drugs Market Competitive Situation and Trends
2.5.1 Parkinson's Disease (PD) Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Parkinson's Disease (PD) Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Parkinson's Disease (PD) Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Parkinson's Disease (PD) Drugs Market
2.8 Key Manufacturers Parkinson's Disease (PD) Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Parkinson's Disease (PD) Drugs Status and Outlook by Region
3.1 Global Parkinson's Disease (PD) Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Parkinson's Disease (PD) Drugs Historic Market Size by Region
3.2.1 Global Parkinson's Disease (PD) Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Parkinson's Disease (PD) Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Parkinson's Disease (PD) Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Parkinson's Disease (PD) Drugs Forecasted Market Size by Region
3.3.1 Global Parkinson's Disease (PD) Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Parkinson's Disease (PD) Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Parkinson's Disease (PD) Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Parkinson's Disease (PD) Drugs by Application
4.1 Parkinson's Disease (PD) Drugs Market Segment by Application
4.1.1 Hospital
4.1.2 Family
4.2 Global Parkinson's Disease (PD) Drugs Market Size by Application
4.2.1 Global Parkinson's Disease (PD) Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Parkinson's Disease (PD) Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Parkinson's Disease (PD) Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Parkinson's Disease (PD) Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Parkinson's Disease (PD) Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Parkinson's Disease (PD) Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Parkinson's Disease (PD) Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Parkinson's Disease (PD) Drugs Sales Breakdown by Application (2018-2023)
5 North America Parkinson's Disease (PD) Drugs by Country
5.1 North America Parkinson's Disease (PD) Drugs Historic Market Size by Country
5.1.1 North America Parkinson's Disease (PD) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Parkinson's Disease (PD) Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Parkinson's Disease (PD) Drugs Sales in Value by Country (2018-2023)
5.2 North America Parkinson's Disease (PD) Drugs Forecasted Market Size by Country
5.2.1 North America Parkinson's Disease (PD) Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Parkinson's Disease (PD) Drugs Sales in Value by Country (2024-2029)
6 Europe Parkinson's Disease (PD) Drugs by Country
6.1 Europe Parkinson's Disease (PD) Drugs Historic Market Size by Country
6.1.1 Europe Parkinson's Disease (PD) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Parkinson's Disease (PD) Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Parkinson's Disease (PD) Drugs Sales in Value by Country (2018-2023)
6.2 Europe Parkinson's Disease (PD) Drugs Forecasted Market Size by Country
6.2.1 Europe Parkinson's Disease (PD) Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Parkinson's Disease (PD) Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Parkinson's Disease (PD) Drugs by Region
7.1 Asia-Pacific Parkinson's Disease (PD) Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Parkinson's Disease (PD) Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Parkinson's Disease (PD) Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Parkinson's Disease (PD) Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Parkinson's Disease (PD) Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Parkinson's Disease (PD) Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Parkinson's Disease (PD) Drugs Sales in Value by Region (2024-2029)
8 Latin America Parkinson's Disease (PD) Drugs by Country
8.1 Latin America Parkinson's Disease (PD) Drugs Historic Market Size by Country
8.1.1 Latin America Parkinson's Disease (PD) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Parkinson's Disease (PD) Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Parkinson's Disease (PD) Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Parkinson's Disease (PD) Drugs Forecasted Market Size by Country
8.2.1 Latin America Parkinson's Disease (PD) Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Parkinson's Disease (PD) Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Parkinson's Disease (PD) Drugs by Country
9.1 Middle East and Africa Parkinson's Disease (PD) Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Parkinson's Disease (PD) Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Parkinson's Disease (PD) Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Parkinson's Disease (PD) Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Parkinson's Disease (PD) Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Parkinson's Disease (PD) Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Parkinson's Disease (PD) Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Boehringer Ingelheim
10.1.1 Boehringer Ingelheim Company Information
10.1.2 Boehringer Ingelheim Introduction and Business Overview
10.1.3 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Boehringer Ingelheim Parkinson's Disease (PD) Drugs Products Offered
10.1.5 Boehringer Ingelheim Recent Development
10.2 GlaxoSmithKline
10.2.1 GlaxoSmithKline Company Information
10.2.2 GlaxoSmithKline Introduction and Business Overview
10.2.3 GlaxoSmithKline Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 GlaxoSmithKline Parkinson's Disease (PD) Drugs Products Offered
10.2.5 GlaxoSmithKline Recent Development
10.3 Novartis
10.3.1 Novartis Company Information
10.3.2 Novartis Introduction and Business Overview
10.3.3 Novartis Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Novartis Parkinson's Disease (PD) Drugs Products Offered
10.3.5 Novartis Recent Development
10.4 Teva Pharmaceutical Industries
10.4.1 Teva Pharmaceutical Industries Company Information
10.4.2 Teva Pharmaceutical Industries Introduction and Business Overview
10.4.3 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Teva Pharmaceutical Industries Parkinson's Disease (PD) Drugs Products Offered
10.4.5 Teva Pharmaceutical Industries Recent Development
10.5 AbbVie
10.5.1 AbbVie Company Information
10.5.2 AbbVie Introduction and Business Overview
10.5.3 AbbVie Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 AbbVie Parkinson's Disease (PD) Drugs Products Offered
10.5.5 AbbVie Recent Development
10.6 Abital Pharma
10.6.1 Abital Pharma Company Information
10.6.2 Abital Pharma Introduction and Business Overview
10.6.3 Abital Pharma Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Abital Pharma Parkinson's Disease (PD) Drugs Products Offered
10.6.5 Abital Pharma Recent Development
10.7 Addex Therapeutics
10.7.1 Addex Therapeutics Company Information
10.7.2 Addex Therapeutics Introduction and Business Overview
10.7.3 Addex Therapeutics Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Addex Therapeutics Parkinson's Disease (PD) Drugs Products Offered
10.7.5 Addex Therapeutics Recent Development
10.8 Biogen
10.8.1 Biogen Company Information
10.8.2 Biogen Introduction and Business Overview
10.8.3 Biogen Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Biogen Parkinson's Disease (PD) Drugs Products Offered
10.8.5 Biogen Recent Development
10.9 Eisai
10.9.1 Eisai Company Information
10.9.2 Eisai Introduction and Business Overview
10.9.3 Eisai Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Eisai Parkinson's Disease (PD) Drugs Products Offered
10.9.5 Eisai Recent Development
10.10 Eli Lilly
10.10.1 Eli Lilly Company Information
10.10.2 Eli Lilly Introduction and Business Overview
10.10.3 Eli Lilly Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Eli Lilly Parkinson's Disease (PD) Drugs Products Offered
10.10.5 Eli Lilly Recent Development
10.11 F. Hoffmann-La Roche
10.11.1 F. Hoffmann-La Roche Company Information
10.11.2 F. Hoffmann-La Roche Introduction and Business Overview
10.11.3 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.11.4 F. Hoffmann-La Roche Parkinson's Disease (PD) Drugs Products Offered
10.11.5 F. Hoffmann-La Roche Recent Development
10.12 H. Lundbeck
10.12.1 H. Lundbeck Company Information
10.12.2 H. Lundbeck Introduction and Business Overview
10.12.3 H. Lundbeck Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.12.4 H. Lundbeck Parkinson's Disease (PD) Drugs Products Offered
10.12.5 H. Lundbeck Recent Development
10.13 Impax Laboratories
10.13.1 Impax Laboratories Company Information
10.13.2 Impax Laboratories Introduction and Business Overview
10.13.3 Impax Laboratories Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Impax Laboratories Parkinson's Disease (PD) Drugs Products Offered
10.13.5 Impax Laboratories Recent Development
10.14 Kyowa Hakko Kirin
10.14.1 Kyowa Hakko Kirin Company Information
10.14.2 Kyowa Hakko Kirin Introduction and Business Overview
10.14.3 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Kyowa Hakko Kirin Parkinson's Disease (PD) Drugs Products Offered
10.14.5 Kyowa Hakko Kirin Recent Development
10.15 Otsuka Pharmaceutical
10.15.1 Otsuka Pharmaceutical Company Information
10.15.2 Otsuka Pharmaceutical Introduction and Business Overview
10.15.3 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Otsuka Pharmaceutical Parkinson's Disease (PD) Drugs Products Offered
10.15.5 Otsuka Pharmaceutical Recent Development
10.16 Pfizer
10.16.1 Pfizer Company Information
10.16.2 Pfizer Introduction and Business Overview
10.16.3 Pfizer Parkinson's Disease (PD) Drugs Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Pfizer Parkinson's Disease (PD) Drugs Products Offered
10.16.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Parkinson's Disease (PD) Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Parkinson's Disease (PD) Drugs Industrial Chain Analysis
11.4 Parkinson's Disease (PD) Drugs Market Dynamics
11.4.1 Parkinson's Disease (PD) Drugs Industry Trends
11.4.2 Parkinson's Disease (PD) Drugs Market Drivers
11.4.3 Parkinson's Disease (PD) Drugs Market Challenges
11.4.4 Parkinson's Disease (PD) Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Parkinson's Disease (PD) Drugs Distributors
12.3 Parkinson's Disease (PD) Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
